NCT06157580

Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Anna Stanhewicz, PhD · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.

Conditions

• Preeclampsia

Interventions

Type	Name	Description
DRUG	Compound 21	differences in vasodilation to compound 21 in the skin between groups
DRUG	Angiotensin II	differences in vasoconstriction to angiotensin II in the skin between groups

Timeline

• Start date: 2023-12-08
• Primary completion: 2024-10-24
• Completion: 2024-12-10
• First posted: 2023-12-06
• Last updated: 2024-12-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study